[go: up one dir, main page]

MX2019012000A - Constructo genetico para usarse en el tratamiento de un transtorno neurodegenerativo o accidente cerebrovascular. - Google Patents

Constructo genetico para usarse en el tratamiento de un transtorno neurodegenerativo o accidente cerebrovascular.

Info

Publication number
MX2019012000A
MX2019012000A MX2019012000A MX2019012000A MX2019012000A MX 2019012000 A MX2019012000 A MX 2019012000A MX 2019012000 A MX2019012000 A MX 2019012000A MX 2019012000 A MX2019012000 A MX 2019012000A MX 2019012000 A MX2019012000 A MX 2019012000A
Authority
MX
Mexico
Prior art keywords
treatment
stroke
disease
neurodegenerative disorder
genetic construct
Prior art date
Application number
MX2019012000A
Other languages
English (en)
Inventor
Martin Keith
Widdowson Peter
Original Assignee
Quethera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quethera Ltd filed Critical Quethera Ltd
Publication of MX2019012000A publication Critical patent/MX2019012000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La invención proporciona constructos genéticos y vectores recombinantes que comprenden dichos constructos. Los constructos y vectores se pueden utilizar en métodos de terapia génica para el tratamiento, prevención o mejora de un trastorno neurodegenerativo, que incluye enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, enfermedad de las neuronas motoras, o para el tratamiento contra accidente cerebrovascular, o para promover la regeneración y/o supervivencia de nervios.
MX2019012000A 2017-04-05 2018-03-28 Constructo genetico para usarse en el tratamiento de un transtorno neurodegenerativo o accidente cerebrovascular. MX2019012000A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1705484.2A GB201705484D0 (en) 2017-04-05 2017-04-05 Genetic construct
PCT/GB2018/050824 WO2018185468A1 (en) 2017-04-05 2018-03-28 Genetic construct for use in the treatment of neurodegenerative disorder or stroke

Publications (1)

Publication Number Publication Date
MX2019012000A true MX2019012000A (es) 2020-01-27

Family

ID=58682577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012000A MX2019012000A (es) 2017-04-05 2018-03-28 Constructo genetico para usarse en el tratamiento de un transtorno neurodegenerativo o accidente cerebrovascular.

Country Status (14)

Country Link
US (1) US20200046850A1 (es)
EP (1) EP3606546B1 (es)
JP (1) JP7296321B2 (es)
KR (1) KR102616629B1 (es)
CN (1) CN110809476B (es)
AU (1) AU2018248651B2 (es)
CA (1) CA3058549A1 (es)
ES (1) ES2881176T3 (es)
GB (1) GB201705484D0 (es)
MX (1) MX2019012000A (es)
PL (1) PL3606546T3 (es)
PT (1) PT3606546T (es)
RU (1) RU2757932C2 (es)
WO (1) WO2018185468A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534837A (ja) * 2017-09-27 2020-12-03 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 活性細胞を含む方法、組成物、及び移植可能な要素
CA3120638A1 (en) * 2018-12-19 2020-06-25 Versameb Ag Rna encoding a protein and a signal peptide with a hydrophobic amino-terminal end
EP3936152A4 (en) 2019-03-04 2022-12-07 Tokyo Metropolitan Institute of Medical Science Nucleic acid construct encoding trk fragment and use thereof
BR112021019139A2 (pt) * 2019-03-27 2021-11-30 Sigilon Therapeutics Inc Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
CN118256562A (zh) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用
WO2024161142A1 (en) 2023-02-02 2024-08-08 Quethera Limited Recombinant adeno-associated virus vector
EP4413993A1 (en) * 2023-02-10 2024-08-14 Dompe' Farmaceutici S.P.A. Method of obtaining recombinant human brain-derived neurotrophic factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588221C (en) * 1999-06-08 2013-07-09 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US9265843B2 (en) * 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
WO2010069331A2 (en) * 2008-12-19 2010-06-24 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
CN110438125A (zh) * 2012-03-15 2019-11-12 科纳公司 通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
RU2019131098A3 (es) 2021-07-27
JP7296321B2 (ja) 2023-06-22
AU2018248651A1 (en) 2019-10-17
RU2019131098A (ru) 2021-05-05
ES2881176T3 (es) 2021-11-29
CA3058549A1 (en) 2018-10-11
CN110809476A (zh) 2020-02-18
EP3606546A1 (en) 2020-02-12
RU2757932C2 (ru) 2021-10-25
KR102616629B1 (ko) 2023-12-21
CN110809476B (zh) 2024-02-27
AU2018248651B2 (en) 2024-07-25
EP3606546B1 (en) 2021-04-28
WO2018185468A1 (en) 2018-10-11
PT3606546T (pt) 2021-07-12
GB201705484D0 (en) 2017-05-17
US20200046850A1 (en) 2020-02-13
PL3606546T3 (pl) 2021-11-08
KR20200005549A (ko) 2020-01-15
JP2020516244A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
MX2019012000A (es) Constructo genetico para usarse en el tratamiento de un transtorno neurodegenerativo o accidente cerebrovascular.
MX2018005286A (es) Constructo genetico.
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2019014974A (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson.
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
MX2019001920A (es) Arn la terapia contra el cancer.
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
MX2022012490A (es) Vectores de aav para la terapia genica de la retina y el snc.
EP4344741A3 (en) Aav vectors targeted to the central nervous system
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2019005266A (es) Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas.
MX2022010959A (es) Terapia genica para trastornos oculares.
EP3998341A3 (en) Adenoviral vectors
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
ZA202003243B (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite